Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04897009 · ClinicalTrials.gov registry record
Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer
A clinical trial of Invasive Breast Carcinoma, sponsored by Mayo Clinic.
- Active
- Registry status
- 38
- Enrollment target
- 1
- Study location
NCT04897009: Active study of Invasive Breast Carcinoma, sponsored by Mayo Clinic.
NCT04897009 is a study of Invasive Breast Carcinoma that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 38 participants, below the 484-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04897009, a study of Invasive Breast Carcinoma, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences response to treatment, and how the immune system reacts to breast cancer treatment.
Primary Outcome
For each of the ten unique family subtypes, and individual cell population within a histological subtype, will utilize a logistic regression model to identify those markers measured at baseline that are predictive of achieving a pathological complete response. Will also perform classification and regression trees (CART) modeling to get at the interplay of the markers (i.e. cell subtypes), which are all uniformly expressed as percentages.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2028-06-08 |
What the registry record for NCT04897009 still lists
NCT04897009 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 484-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT04897009 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04897009 about?
NCT04897009 is a clinical study titled "Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer". This early phase I trial evaluates the impact of chemotherapy before surgery (neoadjuvant) on the peripheral blood immune phenotype in patients with operable breast cancer. Collecting blood and information from patients with breast cancer may help to understand how the immune system influences respo...
What is the current status of trial NCT04897009?
This trial is currently active not recruiting. The enrollment target is 38 participants. The study started on 2021-06-09. Estimated completion is 2028-06-08.
What conditions does trial NCT04897009 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma.
What interventions are being tested in trial NCT04897009?
The interventions under investigation include: Biospecimen Collection (PROCEDURE).
Who is sponsoring clinical trial NCT04897009?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04897009 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04897009's enrollment target sits among peer trials
38 39th of 45 higher than 7 of 45 other Invasive Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Invasive Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
RECRUITING · Phase 1
-
Breast Cancer Survivorship Biorepository
RECRUITING
-
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
RECRUITING
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
RECRUITING · Phase 3
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI